Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT8 | Q9BYC5 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CD40 | P25942 | 1/20 | 0.40 |
| ▸ | CD40LG | P29965 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974959 | 0.95 | FUT8 (0.69) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL17484228 | 0.95 | FUT8 (0.70) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL14163968 | 0.94 | FUT8 (0.67) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL20685452 | 0.93 | FUT8 (0.67) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL12974350 | 0.92 | FUT8 (0.65) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL20685366 | 0.92 | FUT8 (0.65) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL20685379 | 0.92 | FUT8 (0.65) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL25592672 | 0.92 | FUT8 (0.65) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL13138839 | 0.91 | FUT8 (0.65) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 | |
| SCHEMBL14514300 | 0.91 | FUT8 (0.65) | FUT8CYP1A2CYP2C9MAPK1DNASE1L3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683208-B2 | Bridge compound with N,N-dialkylamino group and application thereof | EVERLIGHT USA, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090054645-A1 | Bridge compound with N, N-dialkylamino group and application thereof | EVERLIGHT USA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-7387667-B1 | Black dye composition and black ink composition | EVERLIGHT USA, INC. (US) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054645-A1 | Bridge compound with N, N-dialkylamino group and application thereof | ALKBH1, ALKBH2, B2M | FUT8 886/4885CYP1A2 92/4885CYP2C9 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.